Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Seymour LK, Calvert AH, Lobbezoo MW, Eisenhauer EA, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies.

Eur J Cancer. 2013 May;49(8):1808-14. doi: 10.1016/j.ejca.2013.01.014. Epub 2013 Feb 18.

PMID:
23428669
2.

Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.

Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, Northen JS, Curtin NJ, Thomas HD, Griffin RJ.

J Med Chem. 2011 Mar 24;54(6):1847-59. doi: 10.1021/jm101493z. Epub 2011 Mar 2.

PMID:
21366300
3.

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.

Salazar R, Plummer R, Oaknin A, Robinson A, Pardo B, Soto-Matos A, Yovine A, Szyldergemajn S, Calvert AH.

Invest New Drugs. 2011 Dec;29(6):1406-13. doi: 10.1007/s10637-010-9488-1. Epub 2010 Jul 10.

PMID:
20623160
4.

The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.

Nutt JE, Razak AR, O'Toole K, Black F, Quinn AE, Calvert AH, Plummer ER, Lunec J.

Br J Cancer. 2010 Feb 2;102(3):553-60. doi: 10.1038/sj.bjc.6605501. Epub 2010 Jan 5.

5.

Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies.

Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G; Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT).

Eur J Cancer. 2009 Mar;45(5):741-6. doi: 10.1016/j.ejca.2008.10.024. Epub 2008 Dec 16. Review.

6.
7.

Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer.

Wilkinson SJ, Kucukmetin A, Cross P, Darby S, Gnanapragasam VJ, Calvert AH, Robson CN, Edmondson RJ.

Hum Pathol. 2008 Aug;39(8):1197-204. doi: 10.1016/j.humpath.2007.12.011. Epub 2008 May 20.

PMID:
18495208
8.

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).

Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA.

Eur J Cancer. 2008 Jan;44(1):19-24. Epub 2007 Sep 24.

PMID:
17890079
9.

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).

Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Eisenhauer EA, Seymour LK.

Eur J Cancer. 2008 Jan;44(1):25-9. Epub 2007 Sep 12.

PMID:
17845846
10.

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, Curtin NJ.

Cancer Res. 2006 May 15;66(10):5354-62.

11.

A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.

Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH.

Clin Cancer Res. 2005 Nov 1;11(21):7834-40.

12.

Fishing for new drugs.

Calvert AH.

J Clin Oncol. 2005 Nov 1;23(31):7780-2. Epub 2005 Oct 3. No abstract available.

PMID:
16204006
13.

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ.

Clin Cancer Res. 2005 May 1;11(9):3402-9.

14.

Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.

Azzabi A, Hughes AN, Calvert PM, Plummer ER, Todd R, Griffin MJ, Lind MJ, Maraveyas A, Kelly C, Fishwick K, Calvert AH, Boddy AV.

Br J Cancer. 2005 Mar 28;92(6):1006-12.

15.

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

Hardcastle IR, Ahmed SU, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin RJ, Guyenne S, Hutton C, Källblad P, Kemp SJ, Kitching MS, Newell DR, Norbedo S, Northen JS, Reid RJ, Saravanan K, Willems HM, Lunec J.

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1515-20.

PMID:
15713419
16.

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, Eisenhauer EA.

J Clin Oncol. 2005 Mar 20;23(9):1859-66. Epub 2005 Feb 7.

PMID:
15699482
17.

Biochemical pharmacology of pemetrexed.

Calvert AH.

Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):13-7. Review.

18.

Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.

Tikhe JG, Webber SE, Hostomsky Z, Maegley KA, Ekkers A, Li J, Yu XH, Almassy RJ, Kumpf RA, Boritzki TJ, Zhang C, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR.

J Med Chem. 2004 Oct 21;47(22):5467-81.

PMID:
15481984
19.

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

Clamp A, Adams M, Atkinson R, Boven E, Calvert AH, Cervantes A, Ganesan T, Lotz J, Vasey P, Cheverton P, Jayson GC.

Gynecol Oncol. 2004 Oct;95(1):114-9.

PMID:
15385119
20.

Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoprotein.

Curtin NJ, Barlow HC, Bowman KJ, Calvert AH, Davison R, Golding BT, Huang B, Loughlin PJ, Newell DR, Smith PG, Griffin RJ.

J Med Chem. 2004 Sep 23;47(20):4905-22.

PMID:
15369395
21.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ.

J Natl Cancer Inst. 2004 Jan 7;96(1):56-67.

PMID:
14709739
22.

Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials.

Atalay G, Biganzoli L, Renard F, Paridaens R, Cufer T, Coleman R, Calvert AH, Gamucci T, Minisini A, Therasse P, Piccart MJ; EORTC Breast Cancer and Early Clinical Studies Groups.

Eur J Cancer. 2003 Nov;39(17):2439-49. Review.

PMID:
14602130
23.

Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.

Sayle KL, Bentley J, Boyle FT, Calvert AH, Cheng Y, Curtin NJ, Endicott JA, Golding BT, Hardcastle IR, Jewsbury P, Mesguiche V, Newell DR, Noble ME, Parsons RJ, Pratt DJ, Wang LZ, Griffin RJ.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3079-82.

PMID:
12941338
24.

Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ.

Clin Cancer Res. 2003 Jul;9(7):2711-8.

25.

2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.

Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DR.

J Natl Cancer Inst. 2003 May 7;95(9):675-82.

PMID:
12734319
26.

Pemetrexed safety and dosing strategy.

Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P, Bunn PA Jr.

Semin Oncol. 2002 Dec;29(6 Suppl 18):24-9. Review.

PMID:
12571807
27.

Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.

Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu XH, Hostomsky Z, Webber SE, Eastman BW, Almassy R, Li J, Curtin NJ, Newell DR, Calvert AH, Griffin RJ, Golding BT.

J Med Chem. 2003 Jan 16;46(2):210-3.

PMID:
12519059
28.

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH.

Mol Cancer Ther. 2002 May;1(7):545-52.

29.

Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z.

J Med Chem. 2002 Nov 7;45(23):4961-74.

PMID:
12408707
30.

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ.

J Clin Oncol. 2002 Jul 15;20(14):3114-21.

PMID:
12118025
31.

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM.

Biochim Biophys Acta. 2002 Jul 18;1587(2-3):194-205. Review.

32.

Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

Batey MA, Wright JG, Azzabi A, Newell DR, Lind MJ, Calvert AH, Boddy AV.

Eur J Cancer. 2002 May;38(8):1081-9.

PMID:
12008196
33.

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.

Simpson AB, Calvert PM, Sludden JA, Boddy AV, Griffin MJ, Schätzlein A, Wilson P, Fishwick K, Wheatley A, Ross GA, Calvert AH, Twelves CJ.

Ann Oncol. 2002 Mar;13(3):399-402.

PMID:
11996470
34.

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.

Paul MJ, Summers Y, Calvert AH, Rustin G, Brampton MH, Thatcher N, Middleton MR.

Melanoma Res. 2002 Apr;12(2):175-8.

PMID:
11930115
35.

Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide.

Thomas HD, Porter DJ, Bartelink I, Nobbs JR, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV.

Br J Clin Pharmacol. 2002 Jan;53(1):83-91.

37.

Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies.

Calvert AH, Egorin MJ.

Eur J Cancer. 2002 Jan;38(1):11-6. No abstract available.

PMID:
11750834
38.

Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer.

Boddy AV, Griffin MJ, Sludden J, Thomas HD, Fishwick K, Wright JG, Plumner ER, Highley M, Calvert AH.

Cancer Chemother Pharmacol. 2001 Jul;48(1):15-21.

PMID:
11488519
39.

In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.

Smith PG, Thomas HD, Barlow HC, Griffin RJ, Golding BT, Calvert AH, Newell DR, Curtin NJ.

Clin Cancer Res. 2001 Jul;7(7):2105-13.

40.

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.

Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ.

Eur J Cancer. 2001 Jul;37(11):1366-71.

PMID:
11435066
41.

Estimation of glomerular filtration rate in cancer patients.

Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH.

Br J Cancer. 2001 Feb;84(4):452-9.

42.

Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours.

Thomas HD, Lind MJ, Ford J, Bleehen N, Calvert AH, Boddy AV.

Cancer Chemother Pharmacol. 2000;45(4):284-90.

PMID:
10755316
44.

Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.

White AW, Almassy R, Calvert AH, Curtin NJ, Griffin RJ, Hostomsky Z, Maegley K, Newell DR, Srinivasan S, Golding BT.

J Med Chem. 2000 Nov 2;43(22):4084-97.

PMID:
11063605
45.

Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.

Griffin RJ, Arris CE, Bleasdale C, Boyle FT, Calvert AH, Curtin NJ, Dalby C, Kanugula S, Lembicz NK, Newell DR, Pegg AE, Golding BT.

J Med Chem. 2000 Nov 2;43(22):4071-83.

PMID:
11063604
46.

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.

Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble ME, Sausville EA, Schultz R, Yu W.

J Med Chem. 2000 Jul 27;43(15):2797-804.

PMID:
10956187
47.

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR.

Clin Cancer Res. 2000 Jul;6(7):2860-7.

48.

Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel.

Hughes AN, Griffin MJ, Newell DR, Calvert AH, Johnston A, Kerr B, Lee C, Liang B, Boddy AV.

Br J Cancer. 2000 May;82(9):1519-27.

49.

Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP).

Barlow HC, Bowman KJ, Curtin NJ, Calvert AH, Golding BT, Huang B, Loughlin PJ, Newell DR, Smith PG, Griffin RJ.

Bioorg Med Chem Lett. 2000 Mar 20;10(6):585-9.

PMID:
10741559
50.

Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.

Smith PG, Marshman E, Calvert AH, Newell DR, Curtin NJ.

Semin Oncol. 1999 Apr;26(2 Suppl 6):63-7.

PMID:
10598557

Supplemental Content

Loading ...
Support Center